SC 13G: LENZ Therapeutics, Inc.

AI Summary

SC 13G filing by LENZ Therapeutics, Inc..

Risk Assessment

Risk Level: low

FAQ

Key Financial Figures

• $0.00001 — me of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securitie

Filing Documents

• p24-1293sc13g.htm (SC 13G) — 109KB
• 0000902664-24-002595.txt ( ) — 111KB

(a)

Item 1(a). Name of Issuer. LENZ Therapeutics, Inc. (the " Issuer ").

(b)

Item 1(b). Address of Issuer's Principal Executive Offices. 445 Marine View Ave., Ste. #320, Del Mar, California 92014.

(a)

Item 2(a). Name of Person Filing. This statement is filed by: (i) Point72 Asset Management, L.P. (" Point72 Asset Management ") with respect to shares of common stock, par value $0.00001 per share (" Common Stock "), of the Issuer held by an investment fund it manages; (ii) Point72 Capital Advisors, Inc. (" Point72 Capital Advisors Inc. ") with respect to shares of Common Stock held by an investment fund managed by Point72 Asset Management; (iii) Point72 Biotech Private Investments, LLC (" Point72 Biotech ") with respect to shares of Common Stock of which it is the holder; (iv) Differentiated Ventures Investments, LLC (" Differentiated Ventures "), the managing member of Point72 Biotech, with respect to the shares of Common Stock held by Point72 Biotech; (v) 72 Investment Holdings, LLC (" 72 Investment Holdings "), the sole member of Differentiated Ventures, with respect to the shares of Common Stock held by Point72 Biotech, and (vi) Steven A. Cohen (" Mr. Cohen ") the sole member of 72 Investment Holdings and sole shareholder of Point72 Capital Advisors Inc., with respect to shares of Common Stock held by Point72 Asset Management, Point72 Capital Advisors Inc., Point72 Biotech, Differentiated Ventures, and 72 Investment Holdings. Point72 Asset Management, Point72 Capital Advisors Inc., Point72 Biotech, Differentiated Ventures, 72 Investment Holdings, and Mr. Cohen have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1 , pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Act.

(b)

Item 2(b). Address of Principal Business Office. The address of the principal business office of (i) Point72 Asset Management, Point72 Capital Advisors Inc., Point72 Biotech, Differentiated Ventures, 72 Investment Holdings, and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.

(c)

Item 2(c). Place of Organization. Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Point72 Biotech, Differentiated Ventures, and 72 Investment Holdings are Delaware limited liability companies. Mr. Cohen is a United States citizen.

(d)

Item 2(d). Title of Class of Securities. Common Stock, par value $0.00001 per share.

(e)

Item 2(e). CUSIP Number. 52635N103 Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a: Not applicable. CUSIP No. 52635N103 13G Page 9 of 10 Pages Item 4. The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on March 22, 2024. Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no shares of Common Stock. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to securities held by an investment fund it manages. Point72 Capital Advisors, Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management, and Point72 Capital Advisors Inc. Differentiated Ventures is the managing member of Point72 Biotech and may be deemed to share beneficial ownership over the shares of Common Stock held by Point72 Biotech. 72 Investment Holdings is the sole member of Differentiated Ventures and may be deemed to share beneficial ownership of the shares of Common Stock of which Differentiated Ventures may be deemed the beneficial owner. The filing of this statement should not be construed as an admission that any of the foregoing persons or any reporting person is, for the purposes of Section 13 of the Act, the beneficial owner of the Common Stock reported herein. Item 5. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ]. Item 6. See Item 2(a). Item 7. Identification

View Full Filing

View this SC 13G filing on SEC EDGAR